Alberto Matteelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/52640/publications.pdf

Version: 2024-02-01

222 papers

8,823 citations

50276 46 h-index 85 g-index

225 all docs 225 docs citations

times ranked

225

8674 citing authors

#	Article	IF	CITATIONS
1	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	6.7	608
2	Latent <i>Mycobacterium tuberculosis</i> li>Infection. New England Journal of Medicine, 2015, 372, 2127-2135.	27.0	578
3	Management of latent <i>Mycobacterium tuberculosis</i> ivinfection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, 2015, 46, 1563-1576.	6.7	475
4	The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2016, 16, 1269-1278.	9.1	334
5	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. European Respiratory Journal, 2014, 44, 23-63.	6.7	256
6	Imported Falciparum Malaria in Europe: Sentinel Surveillance Data from the European Network on Surveillance of Imported Infectious Diseases. Clinical Infectious Diseases, 2002, 34, 572-576.	5.8	228
7	Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1168-1176.	5.6	196
8	Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal, 2007, 30, 623-626.	6.7	179
9	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal, 2009, 33, 871-881.	6.7	163
10	Epidemiology and Clinical Features of Imported Dengue Fever in Europe: Sentinel Surveillance Data from TropNetEurop. Clinical Infectious Diseases, 2002, 35, 1047-1052.	5.8	160
11	TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiology, 2010, 5, 849-858.	2.0	158
12	Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. Aids, 2000, 14, 1985-1991.	2.2	139
13	An epidemiological survey of vulvovaginal candidiasis in Italy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2003, 110, 66-72.	1.1	135
14	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. European Respiratory Journal, 2008, 31, 1155-1159.	6.7	131
15	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 2020, 92, S15-S25.	3.3	126
16	Molecular Epidemiology Study of Exogenous Reinfection in an Area with a Low Incidence of Tuberculosis. Journal of Clinical Microbiology, 2001, 39, 2213-2218.	3.9	123
17	TUBERCULOSIS: EPIDEMIOLOGY AND CONTROL. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014070.	1.3	116
18	Multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> : epidemiology and control. Expert Review of Anti-Infective Therapy, 2007, 5, 857-871.	4.4	101

#	Article	IF	Citations
19	Sexually Transmitted Diseases in Travelers. Clinical Infectious Diseases, 2001, 32, 1063-1067.	5.8	100
20	Extensively drug-resistant tuberculosis: epidemiology and management. Clinical Epidemiology, 2014, 6, 111.	3.0	98
21	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. European Respiratory Journal, 2014, 44, 811-815.	6.7	96
22	Age as a Risk Factor for Severe Manifestations and Fatal Outcome of Falciparum Malaria in European Patients: Observations from TropNetEurop and SIMPID Surveillance Data. Clinical Infectious Diseases, 2003, 36, 990-995.	5.8	93
23	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 2016, 47, 1235-1243.	6.7	92
24	Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malaria Journal, 2004, 3, 5.	2.3	79
25	The Visiting Friends or Relatives Traveler in the 21st Century: Time for a New Definition. Journal of Travel Medicine, 2010, 17, 163-170.	3.0	78
26	Tuberculosis elimination: where are we now?. European Respiratory Review, 2018, 27, 180035.	7.1	76
27	Malaria and anaemia in pregnant women in urban Zanzibar, Tanzania. Annals of Tropical Medicine and Parasitology, 1994, 88, 475-483.	1.6	74
28	Screening for Mutations Related to Atovaquone/Proguanil Resistance in Treatment Failures and Other Imported Isolates ofPlasmodium falciparumin Europe. Journal of Infectious Diseases, 2004, 190, 1541-1546.	4.0	73
29	Imported Schistosomiasis in Europe: Sentinel Surveillance Data from TropNetEurop. Journal of Travel Medicine, 2003, 10, 164-167.	3.0	72
30	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. European Respiratory Journal, 2016, 48, 938-943.	6.7	71
31	miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis. PLoS ONE, 2013, 8, e80149.	2.5	70
32	Travel-associated sexually transmitted infections: an observational cross-sectional study of the GeoSentinel surveillance database. Lancet Infectious Diseases, The, 2013, 13, 205-213.	9.1	69
33	Comparison of effectiveness and safety of imipenem/clavulanate-containing regimens in the treatment of MDR-ÂandÂXDR-TB. European Respiratory Journal, 2016, 47, 1758-1766.	6.7	69
34	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. European Respiratory Journal, 2008, 31, 904-905.	6.7	67
35	A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infectious Diseases, 2011, 11, 3.	2.9	66
36	Role of Th1 and Th2 Cytokines in Immune Response to Uncomplicated Plasmodium falciparum Malaria. Vaccine Journal, 2002, 9, 348-351.	3.1	62

#	Article	IF	Citations
37	Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug–Drug Interactions with Rifamycins. Clinical Pharmacokinetics, 2014, 53, 489-507.	3.5	62
38	The placenta and malaria. Annals of Tropical Medicine and Parasitology, 1997, 91, 803-810.	1.6	61
39	Early tuberculosis treatment monitoring by Xpert® MTB/RIF: Figure 1–. European Respiratory Journal, 2012, 39, 1269-1271.	6.7	61
40	Malaric Placentas. Pathology Research and Practice, 1996, 192, 892-898.	2.3	58
41	Recent developments in the diagnosis and management of tuberculosis. Npj Primary Care Respiratory Medicine, 2016, 26, 16078.	2.6	58
42	Diagnosis of Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis: Current Standards and Challenges. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 169-172.	1.9	56
43	Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. European Respiratory Journal, 2004, 24, 11-17.	6.7	53
44	A scoping review of cost-effectiveness of screening and treatment for latent tuberculosis infection in migrants from high-incidence countries. BMC Health Services Research, 2015, 15, 412.	2.2	53
45	New Antituberculosis Drugs: From Clinical Trial to Programmatic Use. Gastroenterology Insights, 2016, 8, 6569.	1.2	53
46	Prevalence and distribution of soil-transmitted helminth (STH) infections in urban and indigenous schoolchildren in Ortigueira, State of Parana, Brasil: implications for control. Tropical Medicine and International Health, 2000, 5, 302-307.	2.3	50
47	Multiple-Dose Pharmacokinetics of Efavirenz with and without the Use of Rifampicin in HIV-Positive Patients. Current HIV Research, 2007, 5, 349-353.	0.5	50
48	Epidemiological features and case management practices of imported malaria in northern Italy 1991-1995. Tropical Medicine and International Health, 1999, 4, 653-657.	2.3	48
49	Tuberculosis elimination and the challenge of latent tuberculosis. Presse Medicale, 2017, 46, e13-e21.	1.9	48
50	Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative. Eurosurveillance, 2017, 22, .	7.0	46
51	Knowledge, Attitudes, and Practices on Malaria Preventive Measures of Migrants Attending a Public Health Clinic in Northern Italy. Journal of Travel Medicine, 2002, 9, 160-162.	3.0	42
52	Paradoxical Reaction during Tuberculosis Treatment in HIV-Seronegative Patients. Clinical Infectious Diseases, 2006, 42, 893-895.	5.8	42
53	Drug-resistant tuberculosis. Current Opinion in Pulmonary Medicine, 2013, 19, 266-272.	2.6	42
54	Business travel-associated illness: a GeoSentinel analysisâ€. Journal of Travel Medicine, 2018, 25, .	3.0	42

#	Article	IF	CITATIONS
55	The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. International Journal of Infectious Diseases, 2022, 124, S12-S19.	3.3	42
56	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. International Journal of Infectious Diseases, 2019, 83, 72-76.	3.3	41
57	QuantiFERON®-TB Gold test in the identification of latent tuberculosis infection in immigrants. Journal of Infection, 2007, 55, 164-168.	3.3	37
58	Regional Variation in Travel-related Illness acquired in Africa, March 1997–May 2011. Emerging Infectious Diseases, 2014, 20, 532-541.	4.3	37
59	Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. Aids, 2016, 30, 797-801.	2.2	37
60	Supervised Preventive Therapy for Latent Tuberculosis Infection in Illegal Immigrants in Italy. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1653-1655.	5 . 6	35
61	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. Clinical Infectious Diseases, 2008, 46, 958-959.	5.8	35
62	Methicillin-ResistantStaphylococcus aureusST398, Italy. Emerging Infectious Diseases, 2010, 16, 346-348.	4.3	35
63	Efficacy and Tolerability of Topical 1% Cidofovir Cream for the Treatment of External Anogenital Warts in HIV-Infected Persons. Sexually Transmitted Diseases, 2001, 28, 343-346.	1.7	34
64	WHO strategies for the programmatic management of drug-resistant tuberculosis. Expert Review of Respiratory Medicine, 2016, 10, 991-1002.	2.5	34
65	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2016, 62, 1188.2-1190.	5 . 8	34
66	â€~Baggage malaria' in Italy: cryptic malaria explained?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 394.	1.8	33
67	Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1065-1071.	1.2	33
68	Compassionate and optimum use of new tuberculosis drugs. Lancet Infectious Diseases, The, 2015, 15, 1131-1132.	9.1	32
69	Insecticide-impregnated bed nets reduce malaria transmission in rural Zanzibar. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 150-154.	1.8	31
70	Acute Respiratory Distress Syndrome inPlasmodium vivaxMalaria in Traveler Returning From Venezuela. Journal of Travel Medicine, 2006, 13, 112-113.	3.0	31
71	The effectiveness and cost-effectiveness of screening for active tuberculosis among migrants in the EU/EEA: a systematic review. Eurosurveillance, $2018, 23, .$	7.0	31
72	Therapy of uncomplicated falciparum malaria in Europe: MALTHER – a prospective observational multicentre study. Malaria Journal, 2012, 11, 212.	2.3	30

#	Article	IF	CITATIONS
73	Congenital Plasmodium vivax malaria mimicking neonatal sepsis: a case report. Malaria Journal, 2010, 9, 63.	2.3	29
74	Clinical standards for the diagnosis, treatment and prevention of TB infection. International Journal of Tuberculosis and Lung Disease, 2022, 26, 190-205.	1,2	29
75	Malarial infection and birthweight in urban Zanzibar, Tanzania. Annals of Tropical Medicine and Parasitology, 1996, 90, 125-134.	1.6	28
76	Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area. European Respiratory Journal, 2019, 53, 1802077.	6.7	28
77	Short Report: Verruga Peruana in an Italian Traveler from Peru. American Journal of Tropical Medicine and Hygiene, 1994, 50, 143-144.	1.4	28
78	Prevalence of pfcrt point mutations and level of chloroquine resistance in Plasmodium falciparum isolates from Africa. Infection, Genetics and Evolution, 2006, 6, 262-268.	2.3	27
79	Differential Diagnosis of Cervical Mycobacterial Lymphadenitis in Children. Pediatric Infectious Disease Journal, 2010, 29, 629-633.	2.0	27
80	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. European Respiratory Journal, 2018, 52, 1800946.	6.7	27
81	Prevalence and risk factors of HSV-1 and HSV-2 antibodies in European HIV infected women. Sexually Transmitted Infections, 2001, 77, 120-124.	1.9	26
82	Breaking the barriers: Migrants and tuberculosis. Presse Medicale, 2017, 46, e5-e11.	1.9	26
83	Completion of screening for latent tuberculosis infection among immigrants. Epidemiology and Infection, 2005, 133, 179-185.	2.1	25
84	Exogenous reinfection of tuberculosis in a low-burden area. Infection, 2015, 43, 647-653.	4.7	25
85	The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. Eurosurveillance, 2018, 23, .	7.0	25
86	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiologica, 2012, 35, 113-59.	0.1	25
87	The placenta and malaria. Annals of Tropical Medicine and Parasitology, 1997, 91, 803-810.	1.6	23
88	Vaginal colonization with Candida spp. in human immunodeficiency virus – infected women: a cohort study. International Journal of STD and AIDS, 2006, 17, 260-266.	1.1	23
89	Chlamydia trachomatis genital infection in migrant female sex workers in Italy. International Journal of STD and AIDS, 2003, 14, 591-595.	1.1	22
90	Genotyping analyses of tuberculosis transmission among immigrant residents in Italy. Clinical Microbiology and Infection, 2010, 16, 1149-1154.	6.0	22

#	Article	IF	Citations
91	Travel Case Scenarios as a Demonstration of Risk Assessment of VFR Travelers: Introduction to Criteria and Evidenceâ€Based Definition and Framework: Table 1. Journal of Travel Medicine, 2010, 17, 153-162.	3.0	22
92	Advancing global programmatic management of latent tuberculosis infection for at risk populations. European Respiratory Journal, 2016, 47, 1327-1330.	6.7	22
93	Screening for active and latent tuberculosis among asylum seekers in Italy: A retrospective cohort analysis. Travel Medicine and Infectious Disease, 2019, 27, 39-45.	3.0	22
94	Malaria in Illegal Chinese Immigrants, Italy. Emerging Infectious Diseases, 2001, 7, 1055-1058.	4.3	22
95	Malaria in migrants. Parassitologia, 1999, 41, 261-5.	0.5	22
96	Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infectious Diseases, 2009, 9, 142.	2.9	21
97	Short report: Diagnosis of tick-borne relapsing fever by the quantitative buffy coat fluorescence method American Journal of Tropical Medicine and Hygiene, 1999, 60, 738-739.	1.4	21
98	gammadelta T lymphocytes in the peripheral blood of patients with tuberculosis with and without HIV co-infection. Thorax, 2002, 57, 357-360.	5.6	19
99	Multidrug-resistant tuberculosis today. Bulletin of the World Health Organization, 2012, 90, 78-78.	3.3	19
100	Visiting Relatives and Friends (VFR), Pregnant, and Other Vulnerable Travelers. Infectious Disease Clinics of North America, 2012, 26, 625-635.	5.1	19
101	Latent tuberculous infection: ethical considerations in formulating public health policy. International Journal of Tuberculosis and Lung Disease, 2015, 19, 137-140.	1.2	19
102	Major differences in organization and availability of health care and medicines for <scp>HIV/TB</scp> coinfected patients across <scp>E</scp> urope. HIV Medicine, 2015, 16, 544-552.	2.2	19
103	Pediatric Migration and Hepatitis A Risk in Host Population. Journal of Travel Medicine, 1999, 6, 204-206.	3.0	18
104	Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop. Malaria Journal, 2003, 2, 17.	2.3	18
105	Phenotypic and genotypic characterization of Neisseria gonorrhoeae in parts of Italy: detection of a multiresistant cluster circulating in a heterosexual network. Clinical Microbiology and Infection, 2008, 14, 949-954.	6.0	18
106	Tuberculosis elimination: a dream or a reality? The case of Oman. European Respiratory Journal, 2018, 51, 1702027.	6.7	18
107	Neurocysticercosis in an Italian traveler to Latin America American Journal of Tropical Medicine and Hygiene, 1999, 60, 255-256.	1.4	18
108	Serum levels of interleukin-18 in patients with uncomplicated Plasmodium falciparum malaria. European Cytokine Network, 2001, 12, 361-4.	2.0	18

#	Article	IF	Citations
109	Treatment patterns and associated costs for genital warts in Italy. Current Medical Research and Opinion, 2008, 24, 3175-3183.	1.9	17
110	Tuberculosis: are we making it incurable?. European Respiratory Journal, 2013, 42, 5-8.	6.7	17
111	Recommendations for treating children with drug-resistant tuberculosis. Pharmacological Research, 2016, 105, 176-182.	7.1	17
112	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. European Respiratory Journal, 2016, 47, 686-688.	6.7	17
113	Mefloquine versus Quinine plus Sulphalene-Pyrimethamine (Metakelfin) for Treatment of Uncomplicated Imported Falciparum Malaria Acquired in Africa. Antimicrobial Agents and Chemotherapy, 2005, 49, 663-667.	3.2	16
114	Acute Renal Failure Due to Visceral Leishmaniasis by Leishmania infantum Successfully Treated With a Single High Dose of Liposomal Amphotericin B. Journal of Travel Medicine, 2008, 15, 358-360.	3.0	16
115	Reversible Reduction of Nevirapine Plasma Concentrations During Rifampicin Treatment in Patients Coinfected With HIV-1 and Tuberculosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 64-69.	2.1	16
116	Contact investigation based on serial interferon-gamma release assays (IGRA) in children from the hematology-oncology ward after exposure to a patient with pulmonary tuberculosis. Infection, 2013, 41, 827-831.	4.7	16
117	Changing Antimicrobial Resistance Profiles among Neisseria gonorrhoeae Isolates in Italy, 2003 to 2012. Antimicrobial Agents and Chemotherapy, 2014, 58, 5871-5876.	3.2	16
118	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. Journal of Infection, 2018, 76, 44-54.	3.3	16
119	High prevalence of a variant of SENV in intravenous drug user HIVâ€infected patients. Journal of Medical Virology, 2002, 68, 18-23.	5.0	15
120	Impact of Previous ART and of ART Initiation on Outcome of HIV-Associated Tuberculosis. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	15
121	Cefixime and ceftriaxone susceptibility of Neisseria gonorrhoeae in Italy from 2006 to 2010. Clinical Microbiology and Infection, 2012, 18, 558-564.	6.0	15
122	Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13–26 years) enrolled in the VALHIDATE study. Human Vaccines and Immunotherapeutics, 2014, 10, 986-994.	3.3	15
123	Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review <i>versus</i> expert opinion. European Respiratory Journal, 2015, 45, 1170-1173.	6.7	15
124	Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium. European Respiratory Journal, 2018, 51, 1702604.	6.7	15
125	Extensively Drug-Resistant Tuberculosis, Burkina Faso. Emerging Infectious Diseases, 2010, 16, 840-842.	4.3	14
126	Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?. European Respiratory Journal, 2011, 37, 1283-1285.	6.7	14

#	Article	IF	CITATIONS
127	Defining a migrant-inclusive tuberculosis research agenda to end TB. International Journal of Tuberculosis and Lung Disease, 2018, 22, 835-843.	1.2	14
128	Fatal Disseminated Toxoplasmosis During Primary HIV Infection. Current HIV Research, 2007, 5, 273-274.	0.5	13
129	Policies and practices on the programmatic management of latent tuberculous infection: global survey. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1566-1571.	1.2	13
130	Short Report: Primaquine-Tolerant Plasmodium vivax in an Italian Traveler from Guatemala. American Journal of Tropical Medicine and Hygiene, 1996, 55, 472-473.	1.4	13
131	Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998–2000. European Respiratory Journal, 2003, 21, 129-134.	6.7	12
132	Imported malaria in northern Italy: epidemiology and clinical features observed over 18 years in the Teaching Hospital of Brescia. Journal of Travel Medicine, 2018, 25, .	3.0	12
133	Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. Journal of Antimicrobial Chemotherapy, 2012, 67, 469-472.	3.0	11
134	Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2012, 10, 1109-1115.	4.4	11
135	New Italian guidelines for malaria prophylaxis in travellers to endemic areas. Infection, 2014, 42, 239-250.	4.7	11
136	Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries. European Respiratory Journal, 2017, 49, 1602242.	6.7	11
137	Malaria Clusters among Illegal Chinese Immigrants to Europe through Africa. Emerging Infectious Diseases, 2003, 9, 1177-1178.	4.3	10
138	Recent Acquired STD and the Use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): Analysis of the Incidence of Newly Acquired Hepatitis B Infection and Syphilis. Infection, 2008, 36, 46-53.	4.7	10
139	Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2009, 64, 879-883.	3.0	10
140	Trend of ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Italy and analysis of the molecular determinants. Diagnostic Microbiology and Infectious Disease, 2010, 67, 350-354.	1.8	10
141	Tuberculosis and HIV co-infection: do we have a surveillance system in Europe?: Table 1–. European Respiratory Journal, 2011, 38, 1258-1260.	6.7	10
142	Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 2470-2473.	3.0	10
143	Imported Plasmodium vivax Malaria ex Pakistan. Journal of Travel Medicine, 2014, 21, 314-317.	3.0	10
144	Prevalence and Incidence of Syphilis Among South American Transgender Sex Workers in Northern Italy. Sexually Transmitted Diseases, 2006, 33, 334-335.	1.7	9

#	Article	IF	Citations
145	Congenital syphilis in Italy. Sexually Transmitted Infections, 2007, 83, 590-591.	1.9	9
146	Identification of the skin virome in a boy with widespread human papillomavirusâ€2â€positive warts that completely regressed after administration of tetravalent human papillomavirus vaccine. British Journal of Dermatology, 2015, 173, 597-600.	1.5	9
147	Numbers needed to treat to prevent tuberculosis. European Respiratory Journal, 2015, 46, 1838-1839.	6.7	9
148	Crossborder travel and multidrugresistant tuberculosis (MDRTB) in Europe. Travel Medicine and Infectious Disease, 2016, 14, 588-590.	3.0	9
149	The Holy Grail of prevention of sexually transmitted infections in travellers. Sexually Transmitted Infections, 2016, 92, 405-406.	1.9	9
150	Louse-borne relapsing fever in a refugee from Mali. Infection, 2017, 45, 373-376.	4.7	9
151	Building a European database to gather multi-country evidence on active and latent TB screening for migrants. International Journal of Infectious Diseases, 2019, 80, S45-S49.	3.3	9
152	Global tuberculosis prevention: should we start from the beginning?. European Respiratory Journal, 2019, 54, 1901394.	6.7	9
153	Framework for the evaluation of new tests for tuberculosis infection. European Respiratory Journal, 2021, 58, 2004078.	6.7	9
154	Treatment of TB. , 2012, , 154-166.		9
155	Time trend analysis (2009-2016) of antimicrobial susceptibility in Neisseria gonorrhoeae isolated in Italy following the introduction of the combined antimicrobial therapy. PLoS ONE, 2017, 12, e0189484.	2.5	9
156	Reversal of chloroquine resistance of †wild†isolates of Plasmodium falciparum by desipramine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 723-724.	1.8	8
157	Levels of circulating nitrate/nitrite and gamma interferon not increased in uncomplicated malaria. Infection, 1998, 26, 301-303.	4.7	8
158	Respiratory Syndrome and Respiratory Tract Infections in Foreign-Born and National Travelers Hospitalized with Fever in Italy. Journal of Travel Medicine, 2005, 12, 190-196.	3.0	8
159	Multidrug- and extensively drug-resistant TB in persons living with HIV. Expert Review of Respiratory Medicine, 2009, 3, 245-254.	2.5	8
160	Disseminated Mycobacterium genavense infection after immunosuppressive therapy shows underlying new composite heterozygous mutations of \hat{l}^21 subunit of IL-12 receptor gene. Journal of Allergy and Clinical Immunology, 2013, 131, 607-610.	2.9	8
161	The impact of Xpert® MTB/RIF depends on service coordination: experience in Burkina Faso. International Journal of Tuberculosis and Lung Disease, 2015, 19, 285-287.	1.2	8
162	TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up. International Journal of Tuberculosis and Lung Disease, 2021, 25, 823-831.	1.2	8

#	Article	IF	Citations
163	Inappropriate Footwear and Rat-Bite Fever in an International Traveler. Journal of Travel Medicine, 2006, 9, 275-276.	3.0	7
164	Ripped from the headlines: how can we harness communications to control TB?. European Respiratory Journal, 2007, 30, 194-198.	6.7	7
165	Tuberculosis, one disease, many faces. Monaldi Archives for Chest Disease, 2008, 69, 2-4.	0.6	7
166	ADVANCES IN THE TREATMENT OF MALARIA. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012064.	1.3	7
167	Antiretroviral Therapy in HIV-Infected Children With Tuberculosis. Pediatric Infectious Disease Journal, 2018, 37, e117-e125.	2.0	7
168	Incidence of tuberculosis in a community of Senegalese immigrants in Northern Italy. International Journal of Tuberculosis and Lung Disease, 1999, 3, 18-22.	1.2	7
169	Prophylaxis for Tuberculosis in Europe—Ongoing Research. Clinical Infectious Diseases, 1996, 22, S55-S60.	5.8	6
170	Passive sentinel surveillance system for sexually transmitted diseases in primary healthcare sites in Ethiopia, 1991-3. Sexually Transmitted Infections, 2000, 76, 131-133.	1.9	6
171	Imported Malaria in an HIV-Positive Traveler: A Case Report with a Fatal Outcome. Journal of Travel Medicine, 2006, 12, 222-224.	3.0	6
172	QuantiFERON®-TB Gold test for healthcare workers. Journal of Hospital Infection, 2008, 69, 91-92.	2.9	6
173	Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in adolescents in Northern Italy: an observational school-based study. BMC Public Health, 2016, 16, 200.	2.9	6
174	Genetic Resistance Determinants for Cefixime and Molecular Analysis of Gonococci Isolated in Italy. Microbial Drug Resistance, 2017, 23, 247-252.	2.0	6
175	Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. PLoS ONE, 2017, 12, e0189425.	2.5	6
176	Healthcare delivery for HIVâ€positive people with tuberculosis in Europe. HIV Medicine, 2021, 22, 283-293.	2.2	6
177	Failure of Mefloquine Chemoprophylaxis for Malaria in Mozambique. Journal of Travel Medicine, 1995, 2, 260-261.	3.0	5
178	Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop. Infection, 2009, 37, 168-178.	4.7	5
179	Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study). BMC Cancer, 2012, 12, 204.	2.6	5
180	Recrudescence of <i>Plasmodium falciparum </i> malaria in a primigravid woman with anaemia as the only sign of disease. Journal of Obstetrics and Gynaecology, 2014, 34, 356-356.	0.9	5

#	Article	IF	CITATIONS
181	Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting. European Respiratory Journal, 2018, 51, 1702345.	6.7	5
182	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. Antibiotics, 2021, 10, 1355.	3.7	5
183	STI epidemics in the Indian Ocean region: can the phase be assessed?. Sexually Transmitted Infections, 2002, 78, i121-i124.	1.9	4
184	Nodular Lesion of the Skin as Primary Cutaneous Tuberculosis. Journal of Travel Medicine, 2006, 10, 306-308.	3.0	4
185	AUTHORS' CORRIGENDUM. Clinical Microbiology and Infection, 2008, 14, 1087.	6.0	4
186	High incidence of sputum smear negative tuberculosis during HAART in Burkina Faso. European Respiratory Journal, 2008, 32, 1668-1669.	6.7	4
187	Is a new definition required for travelers who visit friends and relatives?. Journal of Travel Medicine, 2010, 17, 430-431.	3.0	4
188	Update on antimicrobial susceptibility and genotype of Neisseria gonorrhoeae isolated in Italy. Diagnostic Microbiology and Infectious Disease, 2012, 72, 288-290.	1.8	4
189	Diabetes and tuberculosis: what else beyond?. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1127-1128.	1.2	4
190	Differences in BCG vaccination and tuberculin skin-test positivity. Lancet Infectious Diseases, The, 2015, 15, 1003.	9.1	4
191	Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bulletin of the World Health Organization, 2018, 96, 386-392.	3.3	4
192	Prevalence of Anti-poliovirus Type 1, 2 and 3 Antibodies in Unvaccinated Italian Travelers. Journal of Travel Medicine, 2004, 11, 34-36.	3.0	3
193	Epidemiological phenotypic characteristics of vaginal yeasts at the Comoros. Mycoses, 2009, 52, 458-461.	4.0	3
194	Cervical Human Papillomavirus Infection and Shedding of Human Immunodeficiency Virus in Cervicovaginal Fluids. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 78-82.	2.1	3
195	Indicator condition-guided HIV testing in Europe: a step forward to HIV control:. European Respiratory Journal, 2013, 42, 572-575.	6.7	3
196	Travel, syphilis and HIV. Travel Medicine and Infectious Disease, 2014, 12, 5-6.	3.0	3
197	Mycobacterium sherrisiiPulmonary Disease, Burkina Faso. Emerging Infectious Diseases, 2015, 21, 2093-2094.	4.3	3
198	Incident genital HPV infections and potential impact of HPV vaccines in adult women living with HIV/AIDS. Human Vaccines and Immunotherapeutics, 2019, 15, 1904-1910.	3.3	3

#	Article	IF	CITATIONS
199	Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300Âmg three times per week. Annals of Clinical Microbiology and Antimicrobials, 2020, 19, 3.	3.8	3
200	Tackling TB in migrants arriving at Europe's southern border. International Journal of Infectious Diseases, 2021, , .	3.3	3
201	Chlamydia trachomatis conjunctivitis in a male teenager: a case report. Infezioni in Medicina, 2014, 22, 140-3.	1.1	3
202	Long Term Treatment with Clarithromycin for Cryptosporidiosis and Emergence of Drug Resistant Disseminated Infection Due to <i>Mycobacterium avium:</i> Case Report. Journal of Chemotherapy, 1998, 10, 474-475.	1.5	2
203	Antimicrobial prevention and therapy for travelers' infection. Expert Review of Anti-Infective Therapy, 2007, 5, 1031-1048.	4.4	2
204	A strange case of Malaria in a Nigerian native boy Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017023.	1.3	2
205	Tuberculosis-a World Health Organization Perspective. , 2017, , 211-228.		2
206	Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families. Annals of Internal Medicine, 2017, 167, 742.	3.9	2
207	Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. BMC Infectious Diseases, 2020, 20, 449.	2.9	2
208	Pulmonary nontuberculous mycobacterial infections and environmental factors: A review of the literature. Respiratory Medicine, 2021, 189, 106660.	2.9	2
209	Tuberculosis trend among native and foreign-born people over a 17Âyear period (2004–2020) in a large province in Northern Italy. Scientific Reports, 2021, 11, 23394.	3.3	2
210	Respiratory Diseases. , 2008, , 561-572.		1
211	Continuous monitoring of implemented tuberculosis control measures in middle-income high-endemic countries. Journal of Hospital Infection, 2011, 77, 178-179.	2.9	1
212	Respiratory Infections. , 2013, , 511-522.		1
213	Screening for Chlamydia trachomatis and Neisseria gonorrhoeae among high-school participants using the Versant CT/GC DNA 1.0 assay (kinetic PCR). Journal of Medical Microbiology, 2014, 63, 1237-1239.	1.8	1
214	In reply. Promoting ethical and evidence-based policies for latent tuberculosis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1258-1259.	1.2	1
215	Chlamydia trachomatis genotypes in school adolescents, Italy. Infection, 2015, 43, 739-741.	4.7	1
216	Corrigendum. Expert Review of Respiratory Medicine, 2009, 3, 447-448.	2.5	0

#	ARTICLE	IF	CITATIONS
217	Delayed Diagnosis of Disseminated Mycobacterium genavense Infection in a Human Immunodeficiency Virus-Negative Young Woman. Infectious Diseases in Clinical Practice, 2011, 19, 286-287.	0.3	0
218	Acute HIV infection at travel clinics – Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 651-652.	9.1	0
219	The Traveler With HIV. , 2019, , 279-286.		O
220	Tuberculosis Preventive Treatment: Key Research Areas and the Clinical Pipeline for New Treatments. , $2021, , 415-421.$		0
221	Severe imported Plasmodium falciparum malaria in children: characteristics and useful factors in the risk stratification. Travel Medicine and Infectious Disease, 2021, 44, 102196.	3.0	O
222	Diagnosis and treatment of tuberculosis infection: can it contribute to achieving tuberculosis elimination?. European Respiratory Journal, 2022, 60, 2200540.	6.7	0